Welcome to our dedicated page for Scorpius Holdings news (Ticker: SCPX), a resource for investors and traders seeking the latest updates and insights on Scorpius Holdings stock.
Scorpius Holdings, Inc. (SCPX) is a biotechnology-focused contract development and manufacturing organization (CDMO) that regularly issues news on its biologics and cell therapy manufacturing activities, strategic initiatives, and capital markets developments. Its updates provide insight into how the company supports pharmaceutical and biotech clients through analytical testing, process development, and cGMP manufacturing at its facilities in San Antonio, Texas.
News releases frequently highlight client collaborations and manufacturing agreements. Examples include Scorpius BioManufacturing’s GMP manufacturing validation agreement with Tivic Health Systems, Inc. for Entolimod™, a TLR5 agonist for Acute Radiation Syndrome, and a collaboration with KaloCyte to enhance manufacturing efficiencies for ErythroMer™, a dried, bio-inspired artificial red blood cell. These announcements illustrate Scorpius’ role in advancing innovative therapeutic programs toward the clinic and potential commercialization.
Investors and industry observers can also follow corporate strategy and restructuring updates, such as cost optimization initiatives, workforce reductions, and consolidation of operations into a single location intended to streamline the business and improve capital efficiency. The company has reported membership in the Medical CBRN Defense Consortium and the launch of Scorpius Ventures, a hybrid fee-and-equity unit designed to support emerging biotech companies and onshore U.S. biomanufacturing in alignment with BIOSECURE Act goals.
Scorpius’ news flow further covers capital markets and listing matters, including announcements about a planned and then cancelled reverse stock split, as well as notices from NYSE American regarding delisting proceedings and filing compliance. By reviewing the SCPX news page, readers can track developments in client partnerships, operational realignment, financing activities, and strategic alternatives that shape the company’s trajectory in the CDMO and biotechnology landscape.
On May 16, 2024, Scorpius Holdings announced the closing of its underwritten public offering of 60,000,000 common units and/or pre-funded units at $0.10 per unit. Each unit includes one share of common stock or a pre-funded warrant and a common warrant with an exercise price of $0.12, exercisable for five years. The offering raised gross proceeds of $6,000,000 before underwriting discounts and expenses. Additionally, underwriters have a 45-day option to purchase up to an extra 9,000,000 shares and/or warrants to cover over-allotments. Net proceeds will fund working capital, corporate purposes, and repay a $750,000 promissory note. ThinkEquity acted as sole book-running manager.
Scorpius Holdings (NYSE American: SCPX) has praised Congress for introducing the bipartisan BIOSECURE Act, aimed at strengthening U.S. pharmaceutical supply chain and reducing dependency on foreign manufacturers. The Act has advanced out of the House Oversight Committee and is expected to be voted on by the end of the year. Scorpius has expanded its U.S.-based production facilities and invested in advanced technologies to align with these legislative goals. CEO Jeff Wolf emphasized the importance of passing the Act to ensure America's health security. Scorpius is committed to supporting U.S. Government-backed pharmaceutical programs and furthering domestic biomanufacturing initiatives.
Scorpius Holdings (NYSE American: SCPX) has achieved a significant milestone with the successful validation of its microbial manufacturing facilities for cGMP (current Good Manufacturing Practice) production. This approval enhances the company's ability to produce high-quality microbial biologic drugs, meeting stringent regulatory and client standards. The validation has led to a backlog of client bookings, reflecting trust in Scorpius' capabilities. Additionally, the company is transitioning its environmental monitoring responsibilities to internal teams, aiming to improve operational efficiency. CEO Jeff Wolf emphasized the importance of this milestone in reinforcing Scorpius' commitment to quality and supporting the development of breakthrough therapies.
Scorpius Holdings, an integrated CDMO, has announced the pricing of its public offering of 60,000,000 common units or pre-funded units at $0.10 per unit. Each unit includes one share of common stock (or a pre-funded warrant) and a common warrant to purchase one share at $0.12. Gross proceeds are expected to be $6,000,000 before expenses, with an option for underwriters to purchase up to an additional 9,000,000 units to cover over-allotments. The offering is set to close on May 16, 2024. Proceeds will fund working capital, general purposes, and repay a $750,000 note. ThinkEquity is the sole manager for this offering.
Scorpius Holdings, Inc. announced the appointment of Shari Udoff-McDonald as VP of Business Development. With over 25 years of experience in biopharma business development, she will lead the business development, marketing, and proposals teams to address the strong demand for flexible mammalian and microbial biomanufacturing services. Scorpius is poised for growth with its commitment to transparency and flexibility in CDMO partnerships.
Scorpius Holdings, Inc provided a 2023 year-end business update highlighting a 570% sequential revenue increase in the fourth quarter of 2023. The company reported $4.8 million in revenue from continuing operations, leading to a positive outlook for significant growth in 2024 and beyond. Scorpius aims to capitalize on the growing large molecule drug substance CDMO market, anticipating becoming cash flow positive by early 2025. The company's financial results showed $6.6 million in contract revenue for 2023, along with increased costs and expenses compared to the previous year.
Summary not available.
Summary not available.
Summary not available.
Summary not available.